ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

BridgeBio and AstraZeneca side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BridgeBioAstraZeneca
studies on the registry484,196
open to participants now11298
phase 3 studies under way9200
reach primary completion within a year2168
programswith a study of their own in two years6118+5 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBridgeBioAstraZeneca
Phase 100%

AstraZeneca: 25 of its 118 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%
Phase 233%

AstraZeneca: 47 of its 118 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

40%
Phase 3

BridgeBio: 3 of its 6 programs at phase 3

  1. infigratinibphase 3
  2. encaleretphase 3
  3. ribitolphase 3
50%

AstraZeneca: 28 of its 118 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%
Approved, new studies

BridgeBio: 1 of its 6 programs at approved, new studies

  1. acoramidisapproved, new study
17%

AstraZeneca: 18 of its 118 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 13 more — sign in to see them all

15%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
BridgeBio2 readouts · 2 phase 3··

BridgeBio, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. infigratinibphase 3 · Jan 0 · NCT06873035
·······

BridgeBio, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. ribitolphase 3 · Sep 0 · NCT05775848
·
AstraZeneca61 readouts · 15 phase 3

AstraZeneca, Nov ’26: 7 programs whose next study reaches primary completion

  1. sonesitatug vedotinphase 3 · Nov 17 · NCT06219941
  2. elecoglipronphase 3 · Nov 18 · NCT07723833
  3. Elecoglipron Test formulation 1 Dose Aphase 1 · Nov 18 · NCT07723833
  4. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  5. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729

and 2 more — sign in to see them all

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 7 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 4 programs whose next study reaches primary completion

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

BridgeBio

New programs 0

None

Reached a new phase 0

None

Study stopped 1

  • acoramidisphase 2 · terminated Oct 14“Study ended by the sponsor due to meeting Study Objectives” · NCT03536767

Primary completion later 0

None

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionBridgeBioAstraZeneca
Stomach Neoplasmsboth · compare here

BridgeBio in Stomach Neoplasms: 1 program

  1. infigratinibphase 3

Their studies: BridgeBio’s studies of Stomach Neoplasms in search

Amyloidosisboth · compare here

BridgeBio in Amyloidosis: 1 program

  1. acoramidisapproved, new study

Their studies: BridgeBio’s studies of Amyloidosis in search

AstraZeneca in Amyloidosis: 2 programs

  1. cliramitugphase 3
  2. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloidosis in search

Urinary Bladder Neoplasmsboth · compare here

BridgeBio in Urinary Bladder Neoplasms: 1 program

  1. infigratinibphase 3

Their studies: BridgeBio’s studies of Urinary Bladder Neoplasms in search

AstraZeneca in Urinary Bladder Neoplasms: 2 programs

  1. datopotamab deruxtecanphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Urinary Bladder Neoplasms in search

Amyloid Neuropathies, Familialboth · compare here

BridgeBio in Amyloid Neuropathies, Familial: 1 program

  1. acoramidisapproved, new study

Their studies: BridgeBio’s studies of Amyloid Neuropathies, Familial in search

AstraZeneca in Amyloid Neuropathies, Familial: 1 program

  1. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloid Neuropathies, Familial in search

Amyloidosis, Hereditary, Transthyretin-Relatedboth · compare here

BridgeBio in Amyloidosis, Hereditary, Transthyretin-Related: 1 program

  1. acoramidisapproved, new study

Their studies: BridgeBio’s studies of Amyloidosis, Hereditary, Transthyretin-Related in search

AstraZeneca in Amyloidosis, Hereditary, Transthyretin-Related: 1 program

  1. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloidosis, Hereditary, Transthyretin-Related in search

Hypoparathyroidismboth · compare here

BridgeBio in Hypoparathyroidism: 1 program

  1. encaleretphase 3

Their studies: BridgeBio’s studies of Hypoparathyroidism in search

AstraZeneca in Hypoparathyroidism: 1 program

  1. eneboparatidephase 3

Their studies: AstraZeneca’s studies of Hypoparathyroidism in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetBridgeBioAstraZeneca
TTRacoramidisruleacoramidisrule
A target, or a pathogen for a vaccine, known for: BridgeBio 2 of 6 · AstraZeneca 68 of 118 programs (31 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).